- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Spinal muscular atrophy
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1.7MB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 763KB)
Risdiplam – March 2021
Risdiplam: Powder for oral solution 0.75 mg per 1 mL, 80 mL; Evrysdi®
Last updated
5 July 2021